{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:54:36Z","timestamp":1791557676976,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p><jats:italic>Burkholderia cepacia<\/jats:italic> (<jats:italic>B. cepacia<\/jats:italic>) is an emerging pathogen of nosocomial infection in pediatric patient carrying cystic fibrosis. The clinical diagnosis and treatment of <jats:italic>B. cepacia<\/jats:italic> infection remains poorly studied. This study outlined the risk factors, antimicrobial susceptibility, and clinical characteristics aiming to improve the treatment of <jats:italic>B. cepacia<\/jats:italic> infection.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective study was conducted based on the 50 cases infection caused by <jats:italic>B. cepacia<\/jats:italic> in children without cystic fibrosis, which were diagnosed in the First Affiliated Hospital of Xiamen University, from January 1st, 2011 to December 31st, 2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 50 children were infected with <jats:italic>B. cepacia<\/jats:italic>, of whom 68% had an underlying health condition, such as cardiovascular disease (23.5%), respiratory disease (17.6%), nervous system disease (14.7%), and neoplastic disease (14.7%). At the onset of <jats:italic>B. cepacia<\/jats:italic> infection, 42 (84%) pediatric patients were in an intensive care unit (ICU), 33 (66%) underwent endotracheal intubation, and 32 (64%) had a central venous catheter (CVC). In addition, hospital-acquired cases were 46 (92%), and healthcare-acquired cases were 4 (12%). The most common infectious sites of <jats:italic>B. cepacia<\/jats:italic> were the respiratory tract (68%), followed by the blood (20%), and the urinary tract (12%). It indicated that <jats:italic>B. cepacia<\/jats:italic> was the most sensitive to ceftazidime (95.65%), followed by trimethoprim-sulfamethoxazole (88.68%), meropenem (82.98%), cefepime (77.78%), and levofloxacin (55.85%). The drug resistance rate of piperacillin-tazobactam, minocycline, aztreonam, cefoperazone-sulbactam and ceftriaxone was higher than 55%. 38 cases were cured or improved, eight had treatment terminated, and four died.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:italic>B. cepacia<\/jats:italic> is an opportunistic pathogen normally found in immunocompromised pediatric patients and highly likely to lead to drug resistance. Nosocomial <jats:italic>B. cepacia<\/jats:italic> infections occurred mostly in patients in the ICU based on our observations. The surveillance of <jats:italic>B. cepacia<\/jats:italic> infections including changing epidemiology and increasing resistance of the microorganism is still very important. Treatment with effective antibiotics such as ceftazidime, meropenem, trimethoprim-sulfamethoxazole is associated with a favorable prognosis.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2023.1115877","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T13:28:38Z","timestamp":1684157318000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Burkholderia cepacia infection in children without cystic fibrosis: a clinical analysis of 50 cases"],"prefix":"10.3389","volume":"11","author":[{"given":"Huixuan","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianrui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bizhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/femspd\/ftx076","article-title":"Detection of misidentifications of species from the Burkholderia cepacia complex and description of a new member, the soil bacterium Burkholderia catarinensis sp. nov","volume":"75","author":"Bach","year":"2017","journal-title":"Pathog Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jinf.2018.07.006","article-title":"Burkholderia cepacia complex infections: more complex than the bacterium name suggest","volume":"77","author":"Sfeir","year":"2018","journal-title":"J Infect"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s10096-020-03960-2","article-title":"Management and outcomes of Burkholderia cepacia complex bacteremia in patients without cystic fibrosis: a retrospective observational study","volume":"39","author":"Lee","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/INF.0000000000002587","article-title":"Major aspects of Burkholderia gladioli and Burkholderia cepacia infections in children","volume":"39","author":"Bedir Demirdag","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s12098-014-1473-9","article-title":"Burkholderia cepacia sepsis among neonates","volume":"81","author":"Patra","year":"2014","journal-title":"Indian J Pediatr"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1128\/9781555816728","volume-title":"Manual of clinical microbiology","author":"Versalovic","year":"2011"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1128\/9781555817381","volume-title":"Manual of clinical microbiology","author":"Jorgensen","year":"2015"},{"key":"B8","doi-asserted-by":"publisher","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","article-title":"Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections","volume":"137","author":"Friedman","year":"2002","journal-title":"Ann Intern Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.mcna.2018.12.008","article-title":"Community-acquired pneumonia and hospital-acquired pneumonia","volume":"103","author":"Lanks","year":"2019","journal-title":"Med Clin North Am"},{"key":"B11","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2010"},{"key":"B12","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2011"},{"key":"B13","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2012"},{"key":"B14","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2013"},{"key":"B15","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2014"},{"key":"B16","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2015"},{"key":"B17","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2016"},{"key":"B18","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2017"},{"key":"B19","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2018"},{"key":"B20","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2019"},{"key":"B21","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2020"},{"key":"B22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.24953\/turkjped.2021.02.005","article-title":"Burkholderia cepacia complex bacteremia outbreaks among non-cystic fibrosis patients in the pediatric unit of a university hospital","volume":"63","author":"T\u00fcfekci","year":"2021","journal-title":"Turk J Pediatr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3349\/ymj.2016.57.1.97","article-title":"Burkholderia sepsis in children as a hospital-acquired infection","volume":"57","author":"Kim","year":"2016","journal-title":"Yonsei Med J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1086\/519177","article-title":"Risk factors for Burkholderia cepacia complex bacteremia among intensive care unit patients without cystic fibrosis: a case-control study","volume":"28","author":"Bressler","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1440-1754.2007.01173.x","article-title":"Two outbreaks of Burkholderia cepacia nosocomial infection in a neonatal intensive care unit","volume":"44","author":"Lee","year":"2008","journal-title":"J Paediatr Child Health"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1093\/cid\/cix559","article-title":"A 17-year nationwide study of Burkholderia cepacia complex bloodstream infections among patients in the United States veterans health administration","volume":"65","author":"El Chakhtoura","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12098-019-03156-3","article-title":"Burkholderia cepacia brain abscess in a term neonate","volume":"87","author":"Pareek","year":"2020","journal-title":"Indian J Pediatr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13256-018-1633-z","article-title":"Infective endocarditis due to Burkholderia cepacia in a neonate: a case report","volume":"12","author":"Yonas","year":"2018","journal-title":"J Med Case Rep"},{"key":"B29","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/01.inf.0000137565.23501.03","article-title":"Hemophagocytic syndrome and Burkholderia cepacia splenic microabscesses in a child with chronic granulomatous disease","volume":"23","author":"Sirinavin","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e230434","DOI":"10.1136\/bcr-2019-230434","article-title":"Macrophage activation syndrome\/haemophagocytic lymphohistiocytosis secondary to Burkholderia cepacia complex septicaemia in an elderly female carrier of X-linked chronic granulomatous disease with extreme lyonisation: \u201ccepacia syndrome\u201d revisited","volume":"12","author":"Urriola","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B31","volume-title":"Performance standards for antimicrobial susceptibility testing","year":"2022"},{"key":"B32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.diagmicrobio.2011.01.008","article-title":"Clinical characteristics and outcomes of patients with Burkholderia cepacia bacteremia in an intensive care unit","volume":"70","author":"Liao","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"B33","volume-title":"The sanford guide to antimicrobial therapy","author":"Gilbert","year":"2022"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1086\/383313","article-title":"Virulence associated with outbreak-related strains of Burkholderia cepacia complex among a cohort of patients with bacteremia","volume":"38","author":"Woods","year":"2004","journal-title":"Clin Infect Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ijantimicag.2008.09.010","article-title":"Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence","volume":"33","author":"Avgeri","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"B36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13052-022-01362-y","article-title":"The efficacy and safety of minocycline as adjuvant therapy in refractory mycoplasma pneumonia in Chinese children: a meta-analysis","volume":"48","author":"Shen","year":"2022","journal-title":"Ital J Pediatr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40272-022-00513-2","article-title":"Safety of quinolones in children: a systematic review and meta-analysis","volume":"24","author":"Li","year":"2022","journal-title":"Paediatr Drugs"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1115877\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T13:28:53Z","timestamp":1684157333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1115877\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":37,"alternative-id":["10.3389\/fped.2023.1115877"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1115877","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"article-number":"1115877"}}